Nurix Therapeutics
Nurix Therapeutics develops small molecule drugs that modulate protein levels to treat cancer, leveraging its proprietary DELigase platform for Targeted Protein Modulation.
Services
Nurix Therapeutics specializes in developing small molecule drugs for the modulation of protein levels within cells. Their proprietary DELigase platform leverages E3 ligase expertise and DNA-encoded libraries to enable targeted protein modulation. They offer both Targeted Protein Degradation to eliminate disease-causing proteins and Targeted Protein Elevation to increase beneficial proteins. Their current research and development efforts focus on advancing clinical-stage drug candidates for treating hematologic malignancies, solid tumors, and inflammatory diseases.
Products
Nurix Therapeutics has developed a portfolio of innovative small molecules designed to modulate protein activity. Key product candidates include NX-5948, an oral BTK degrader for B-cell malignancies; NX-2127, an oral BTK and cereblon neosubstrate degrader; NX-1607, an oral CBL-B inhibitor aimed at enhancing immune responses; and NX-0479/GS-6791, an oral IRAK4 degrader that targets both scaffold and kinase functions of the IRAK4 protein kinase to block inflammatory responses. These candidates are currently undergoing Phase 1 clinical trials.
Collaborations
Nurix Therapeutics has strategic collaborations with major pharmaceutical companies such as Gilead Sciences, Sanofi, and Pfizer. These partnerships focus on the discovery and development of innovative therapies using the proprietary DELigase platform. These collaborations aim to leverage Nurix's expertise in targeted protein modulation to address unmet medical needs and develop novel therapeutic approaches.
Clinical Trials
Nurix Therapeutics is conducting multiple Phase 1 clinical trials for its protein modulation portfolio. The trials are investigating treatments for relapsed/refractory B-cell malignancies and immuno-oncology indications. Key candidates in these trials include NX-5948 and NX-2127, both targeting BTK, and NX-1607, a CBL-B inhibitor with potential applications in multiple oncology indications. The company’s innovative approach seeks to provide new treatment options for patients who have failed prior therapies.
DELigase Platform
The DELigase platform is Nurix Therapeutics' proprietary technology for targeted protein modulation. It includes a collection of over 90 E3 ligases and DNA-encoded libraries consisting of more than five billion molecules. The platform allows for the identification of small molecules that can modulate protein levels by either degrading disease-causing proteins or elevating beneficial ones. This platform underpins the company's efforts in developing targeted protein modulators for various therapeutic applications, especially in oncology and inflammatory diseases.